| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan;
Clinical Immunology, Department of Internal Medicine, University Hospital, Zürich, Switzerland;
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan;
§
Department of Surgery, Institute of Medical Science, University of Tokyo, Tokyo, Japan;
¶
Department of Allergology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; and
||
Laboratory Animal Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
Fas/Apo-1 (CD95)-Fas ligand (FasL) system has been implicated in the suppression and stimulation of immune responses. We examined the induction of antitumor immunity with neuroblastoma Neuro-2a cells transfected with FasL cDNA (Neuro-2a+FasL). Neuro-2a+FasL cells expressed FasL on the cell surface and secreted soluble FasL. Histologic and flow cytometric analyses revealed that Neuro-2a+FasL cells caused neutrophils to infiltrate into the injected site, resulting in strong inflammation. Neutrophil infiltration was inhibited by treatment with anti-FasL mAb and did not occur in Fas-deficient lpr mice. Normal syngeneic mice rejected Neuro-2a+FasL cells after the inflammation and acquired tumor-specific protective immunity. CD8+ T cells were responsible for the antitumor immunity. Neuro-2a+FasL cells formed tumors after far longer latency compared with mock-transfected Neuro-2a+Neo cells in nude mice, and immune competent mice rejected Neuro-2a cells but not sarcoma S713a cells when they were injected with Neuro-2a+FasL cells in a mixture. These results suggest that neutrophils attracted through the Fas-FasL system may impair tumor cells by inflammation at the initial step, followed by development of CD8+ T cell-dependent tumor-specific antitumor immunity, leading to complete eradication of tumor cells. Importantly, the treatment with Neuro-2a+FasL cells exhibited therapeutic efficacy against growing tumors.
This article has been cited by other articles:
|
|
 |
|
  J.-M. Navenot, N. Fujii, and S. C. Peiper KiSS1 Metastasis Suppressor Gene Product Induces Suppression of Tyrosine Kinase Receptor Signaling to Akt, Tumor Necrosis Factor Family Ligand Expression, and Apoptosis Mol. Pharmacol., May 1, 2009; 75(5): 1074 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Autefage, V. Albinet, V. Garcia, H. Berges, M.-L. Nicolau, N. Therville, M.-F. Altie, C. Caillaud, T. Levade, and N. Andrieu-Abadie Lysosomal Serine Protease CLN2 Regulates Tumor Necrosis Factor-{alpha}-mediated Apoptosis in a Bid-dependent Manner J. Biol. Chem., April 24, 2009; 284(17): 11507 - 11516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Newsom-Davis, D. Wang, L. Steinman, P. F-T. Chen, L.-X. Wang, A. K. Simon, and G. R. Screaton Enhanced Immune Recognition of Cryptic Glycan Markers in Human Tumors Cancer Res., March 1, 2009; 69(5): 2018 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liu, D. R. Breiter, G. Zheng, and A. Chen Enhanced Antitumor Responses Elicited by Combinatorial Protein Transfer of Chemotactic and Costimulatory Molecules J. Immunol., March 1, 2007; 178(5): 3301 - 3306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chen, S. Liu, D. Park, Y. Kang, and G. Zheng Depleting Intratumoral CD4+CD25+ Regulatory T Cells via FasL Protein Transfer Enhances the Therapeutic Efficacy of Adoptive T Cell Transfer Cancer Res., February 1, 2007; 67(3): 1291 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Escaffit, O. Vaute, M. Chevillard-Briet, B. Segui, Y. Takami, T. Nakayama, and D. Trouche Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression Mol. Cell. Biol., January 15, 2007; 27(2): 554 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Guo, M. Zhang, H. Tang, and X. Cao Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines Blood, September 15, 2005; 106(6): 2033 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Milhas, O. Cuvillier, N. Therville, P. Clave, M. Thomsen, T. Levade, H. Benoist, and B. Segui Caspase-10 Triggers Bid Cleavage and Caspase Cascade Activation in FasL-induced Apoptosis J. Biol. Chem., May 20, 2005; 280(20): 19836 - 19842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tardy, H. Autefage, V. Garcia, T. Levade, and N. Andrieu-Abadie Mannose 6-Phosphorylated Proteins Are Required for Tumor Necrosis Factor-induced Apoptosis: DEFECTIVE RESPONSE IN I-CELL DISEASE FIBROBLASTS J. Biol. Chem., December 17, 2004; 279(51): 52914 - 52923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Doering, B Begue, M J Lentze, F Rieux-Laucat, O Goulet, J Schmitz, N Cerf-Bensussan, and F M Ruemmele Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease Gut, November 1, 2004; 53(11): 1632 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Saff, E. S. Spanjaard, A. M. Hohlbaum, and A. Marshak-Rothstein Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells J. Immunol., June 1, 2004; 172(11): 6598 - 6606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Samel, D. Muller, J. Gerspach, C. Assohou-Luty, G. Sass, G. Tiegs, K. Pfizenmaier, and H. Wajant Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation J. Biol. Chem., August 22, 2003; 278(34): 32077 - 32082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Buonocore, F. Paulart, A. Le Moine, M. Braun, I. Salmon, S. Van Meirvenne, K. Thielemans, M. Goldman, and V. Flamand Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo Blood, February 15, 2003; 101(4): 1469 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Knox, A. E. Milner, N. K. Green, A. G. Eliopoulos, and L. S. Young Inhibition of Metalloproteinase Cleavage Enhances the Cytotoxicity of Fas Ligand J. Immunol., January 15, 2003; 170(2): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Igney and P. H. Krammer Immune escape of tumors: apoptosis resistance and tumor counterattack J. Leukoc. Biol., June 1, 2002; 71(6): 907 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. de Thonel, A. Bettaieb, C. Jean, G. Laurent, and A. Quillet-Mary Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells Blood, December 15, 2001; 98(13): 3770 - 3777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hohlbaum, M. S. Gregory, S.-T. Ju, and A. Marshak-Rothstein Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors J. Immunol., December 1, 2001; 167(11): 6217 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Hohlbaum, S. Moe, and A. Marshak-Rothstein Opposing Effects of Transmembrane and Soluble Fas Ligand Expression on Inflammation and Tumor Cell Survival J. Exp. Med., April 3, 2000; 191(7): 1209 - 1220. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
